EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, synthesis and in silico molecular modelling studies of 2-Hydrazineyl-2-oxoethyl-4-(1H-pyrrol-1-yb) benzoate derivatives: a potent dual DHFR and ENR-reductase inhibitors with antitubercular, antibacterial and cytotoxic potential

Mater H Mahnashi, Prem Kumar Santhemavathuru Ramachandraiah, Ahmed Abdullah Al Awadh, Ibrahim Abdullah Almazni, Yahya I Asiri, Ibrahim Ahmed Shaikh, Basheerahmed Abdulaziz Mannasaheb, Sravanthi Avunoori, Aejaz Abdullatif Khan iD, Shrinivas D Joshi iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0323702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Mater H Mahnashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia. Hauptthemen laut MEDLINE: Antitubercular Agents, Folic Acid Antagonists, Anti-Bacterial Agents, Oxidoreductases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research, King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current research includes the study of 28 new 2-hydrazineyl-2-oxoethyl-4-(1 H -pyrrol-1-yl) benzoate derivatives as antitubercular, antibacterial, and enoyl-ACP reductase enzyme inhibitors. SYBYL-X.2.0 was used to investigate the molecular docking of ENR-ACP reductase/InhA in complex with 1-cyclohexyl- N -(3,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide (PDB ID:4TZK) and MtDHFR in complex with methotrexate (PDB ID:1DF7). All of the reported derivatives have two or more H-bonding interactions with TYR158 and the cofactor NAD + , which fit snugly into InhA’s binding pocket, with MIC values of 0.8–3.12 µg/mL, 0.4–3.12 µg/mL, and 1.6–12.5 µg/mL [4(a-e), 5(a-p), 6(a-e)]. Also, the molecular H-bonding interactions of reported molecules with amino acids ARG32 and ARG60 of MtDHFR showed the interaction of molecules with targeted site. All of the reported compounds showed good activity against M. tuberculosis H 37 Rv, Gram-negative E.coli , and Gram-positive S. aureus , respectively. Compounds 5b and 6d showed highest antitubercular activity with the MIC value of 0.8 µg/mL. InhA inhibition was good to moderate in the tested compounds, with IC 50 inhibition ranging from 9 to 51% at 50μM; and MtDHFR inhibition was good with IC 50 values ranging from 23 to 153 µM compared to trimethoprim at 92 µM. The most potent compounds exhibiting dual enzyme inhibition were further evaluated for cytotoxicity in mammalian cells using the human lung cancer cell line A549. These compounds demonstrated significant cytotoxic effects, with IC 50 values ranging from 255 to 319 µg/mL. In comparison, the standard antitubercular drug isoniazid exhibited an IC 50 value greater than 450 µg/mL, while the anticancer drug cisplatin showed an IC 50 value of 9.9 µg/mL. These molecules represent excellent future therapeutic possibilities with potential use in the biological and medical sciences due to the compounds’ pronounced docking properties and biological activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsFolic Acid AntagonistsAnti-Bacterial AgentsOxidoreductasesBenzoatesEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)HumansMolecular Docking SimulationTetrahydrofolate DehydrogenaseMicrobial Sensitivity TestsDrug DesignMycobacterium tuberculosisCell Line, TumorBacterial Proteins

Substanzen

Antitubercular AgentsFolic Acid AntagonistsAnti-Bacterial AgentsTetrahydrofolate DehydrogenaseOxidoreductasesBenzoatesEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Bacterial ProteinsInhA protein, Mycobacterium

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Department of Pharmaceutical Quality Assurance, Sree Siddaganga College of Pharmacy, Tumkur, Karnataka, India.
  • Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, Najran, Saudi Arabia.
  • Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
  • Department of Pharmacology, College of Pharmacy, Najran University, Najran, Saudi Arabia.
  • Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Riyadh, Saudi Arabia.

ORCID-Profile: Aejaz Abdullatif Khan, Shrinivas D Joshi

Förderung

  • Deanship of Scientific Research, King Khalid University

Zitieren

APA

Mahnashi, M. H., Ramachandraiah, P. K. S., Al Awadh, A. A., Almazni, I. A., Asiri, Y. I., Shaikh, I. A., Mannasaheb, B. A., Avunoori, S., Khan, A. A., & Joshi, S. D. (2025). Design, synthesis and in silico molecular modelling studies of 2-Hydrazineyl-2-oxoethyl-4-(1H-pyrrol-1-yb) benzoate derivatives: a potent dual DHFR and ENR-reductase inhibitors with antitubercular, antibacterial and cytotoxic potential. PLOS One. https://doi.org/10.1371/journal.pone.0323702

Vancouver

Mahnashi MH, Ramachandraiah PKS, Al Awadh AA, Almazni IA, Asiri YI, Shaikh IA, et al. Design, synthesis and in silico molecular modelling studies of 2-Hydrazineyl-2-oxoethyl-4-(1H-pyrrol-1-yb) benzoate derivatives: a potent dual DHFR and ENR-reductase inhibitors with antitubercular, antibacterial and cytotoxic potential. PLOS One. 2025. doi:10.1371/journal.pone.0323702

BibTeX
@article{Mahnashi2025,
  author = {Mahnashi, Mater H and Ramachandraiah, Prem Kumar Santhemavathuru and Al Awadh, Ahmed Abdullah and Almazni, Ibrahim Abdullah and Asiri, Yahya I and Shaikh, Ibrahim Ahmed and Mannasaheb, Basheerahmed Abdulaziz and Avunoori, Sravanthi and Khan, Aejaz Abdullatif and Joshi, Shrinivas D},
  title = {Design, synthesis and in silico molecular modelling studies of 2-Hydrazineyl-2-oxoethyl-4-(1H-pyrrol-1-yb) benzoate derivatives: a potent dual DHFR and ENR-reductase inhibitors with antitubercular, antibacterial and cytotoxic potential},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0323702}
}
Kostenlos starten →